Analgesia method
AssigneeVernalis (R&D) Ltd
InventorsColin Stanley Goodchild, Raymond Nadeson
Life of this patent
Estimating the term…
Abstract
Opioid tolerance is reduced by treating the patient with a neurosteroid of formula (I) wherein R1 is H or methyl; R2 is OH and R3 is H, or R2 and R3 taken together are O; R4 is H or methyl; R5 and R6 are each H, or R5 and R5 taken together are O; R7 is H or methyl; and R8 is H, OH, —OC(═O)CH3, SH, —SC(═O)CH3, Cl, Br or F.
Claims11
A method for reducing opioid tolerance in a patient undergoing treatment with that opioid who has become tolerant thereto as a result of that treatment, comprising:
- administering to said patient an effect amount of a compound of formula (I)
- wherein
- R1 is selected from the group consisting of H and methyl;
- R2 is OH:
- R3 is H;
- or R2 and R3 taken together are O;
- R4 is selected from the group consisting of H and methyl;
- R5 and R5 are each H;
- or R5 and R6 taken together are O;
- R7 is selected from the group consisting of H and methyl;
- R8 is selected from the group consisting of H, OH, —OC (═O) CH3, SH, —SC (═O) CH3, Cl, Br and F;
- or a pharmaceutically acceptable derivative thereof;
- said compound of formula (I) being administered either (i) while the patient is also undergoing treatment with said opioid or (ii) after cessation of treatment with said opioid and prior to resumption of treatment with said opioid.
A kit for reducing opioid tolerance in a patient undergoing treatment with that opioid who has become tolerant thereto as a result of that treatment, comprising:
- an effective amount of a compound of formula (I)
- wherein
- R1 is selected from the group consisting of H and methyl;
- R2 is OH:
- R3 is H;
- or R2 and R3 taken together are O;
- R4 is selected from the group consisting of H and methyl;
- R5 and R5 are each H;
- or R5 and R6 taken together are O;
- R7 is selected from the group consisting of H and methyl;
- R8 is selected from the group consisting of H, OH, —OC (═O) CH3, SH, —SC (═O) CH3, Cl, Br and F;
- or a pharmaceutically acceptable derivative thereof;
- instructions for administration of said compound of formula (I) either (i) while the patient is also undergoing treatment with said opioid or (ii) after cessation of treatment with said opioid and prior to resumption of treatment with said opioid in said kit.
A composition for reducing opioid tolerance in a patient undergoing treatment with that opioid who has become tolerant thereto as a result of that treatment, comprising:
- a compound of formula (I)
- wherein
- R1 is selected from the group consisting of H and methyl;
- R2 is OH:
- R3 is H;
- or R2 and R3 taken together are O;
- R4 is selected from the group consisting of H and methyl;
- R5 and R5 are each H;
- or R5 and R6 taken together are O;
- R7 is selected from the group consisting of H and methyl;
- R8 is selected from the group consisting of H, OH, —OC (═O) CH3, SH, —SC (═O) CH3, Cl, Br and F;
- or a pharmaceutically acceptable derivative thereof;
- said compound of formula (I) for administration either (i) while the patient is also undergoing treatment with said opioid or (ii) after cessation of treatment with said opioid and prior to resumption of treatment with said opioid.
Dependencies are inferred from the claim text.